Showing 1 - 9 of 9 Transplant Trials
A Double-blind, Randomized, Controlled Dose Escalation Trial of Autologous Mesenchymal Stromal Cells in Living Donor Kidney Transplant Recipients

Status: Enrolling

Investigator: Ahmed Gaber

Study Coordinator:

Phone:

Kidney transplantation is a good treatment option for people with kidney disease. However, there is still much to learn about how to best care for the transplanted kidney and keep it functioning for a long time. Transplant recipients receive ind ... Read more >

A Phase 2, Randomized, Placebo-Controlled Study to Evaluate Fingolimod for the Abrogation of Interstitial Fibrosis and Tubular Atrophy Following Kidney Transplantation

Status: Enrolling

Investigator: Ahmed Gaber

Study Coordinator: Jack Curtis

Phone: 913.486.9249

This is a randomized, double-blind, placebo-controlled trial in de novo kidney transplant patients to determine if the addition of fingolimod (brand name Gilenya®, candidate name- FTY720) on the background of standard immunosuppression will prev ... Read more >

A PHASE 3, OPEN-LABEL, RANDOMIZED, STANDARD OF CARE-CONTROLLED, PARALLEL ARM STUDY TO DEMONSTRATE EFFICACY AND SAFETY OF ARINA-1 IN THE PREVENTION OF BRONCHIOLITIS OBLITERANS SYNDROME PROGRESSION IN PARTICIPANTS WITH BILATERAL LUNG TRANSPLANT

Status: Enrolling

Investigator: Howard Huang

Study Coordinator: Doris Onyekwere

Phone: 346.238.4586

The goal of this clinical trial is to compare ARINA-1 plus Standard of Care vs Standard of Care alone. The main question it aims to answer are: Evaluate the effectiveness of ARINA-1 in preventing bronchiolitis obliterans syndrome (BOS) progre ... Read more >

A Prospective Study Evaluating the Clinical Outcomes of Ventral Hernias treated Robotically with OviTex® Reinforced Tissue Matrix

Status: Open Not Enrolling

Investigator: Nabil Tariq

Study Coordinator: Nicole Hinton

Phone: 281.755.0796

This study is designed to evaluate the post-operative complications and re-herniations following the use of OviTex in subjects with ventral or inguinal hernias. Up to 160 subjects will participate in the study from up to 20 investigator sites.</ ... Read more >

An Open-Label, Controlled, Randomized Phase 3 Trial Evaluating 12-Month Kidney Function in Highly Sensitized (cPRA =99.9%) Kidney Transplant Patients with Positive Crossmatch Against a Deceased Donor, Using Imlifidase with Standard of Care

Status: Open Not Enrolling

Investigator: Ahmed Gaber

Study Coordinator: Beatriz Efron

Phone: 713.363.8890

An open-label, controlled, randomized Phase 3 trial evaluating 12-month kidney function in highly sensitized (cPRA =99.9%) kidney transplant patients with positive crossmatch against a deceased donor, comparing desensitization using imlifidase w ... Read more >

CARDIO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)

Status: Open Not Enrolling

Investigator: Mahwash Kassi

Study Coordinator: Jan-Michael Ragunton

Phone: 346.238.0218

To evaluate the efficacy of eplontersen compared to placebo for 120 weeks in patients with ATTR-CM receiving available standard of care (SoC). For more information, please visit https://www.cardio-ttransform.com. ... Read more >

Neoadjuvant Combination Therapy of Lenvima® plus Transcatheter Arterial Chemoembolization (TACE) for Transplant-Eligible Patients with Large Hepatocellular Carcinoma

Status: Open Not Enrolling

Investigator: Maen Abdelrahim

Study Coordinator: Elsie Rizk

Phone: 713.441.2557

We propose a regimen of six months neoadjuvant lenvatinib in combination with transcatheter arterial chemoembolization (TACE) prior to liver transplantation in patients with hepatocellular carcinoma (HCC) beyond Milan Criteria. Clinical, outcome ... Read more >

Observational Registry Study with Sub-analysis (Patients Previously Randomized to LAMBDA 001) to Assess ProsperaTM Performance for Detection of CLAD after Lung Transplant (LAMBDA 002)

Status: Open Not Enrolling

Investigator: Howard Huang

Study Coordinator: Nicole Hinton

Phone: 281.755.0796

The LAMBDA 002 registry study is an observational, longitudinal, multi-center study observing patients undergoing lung transplant. ... Read more >

Vaccination Responses in Lung Transplant Recipients

Status: Enrolling

Investigator: Howard Huang

Study Coordinator: Lindsay Barter

Phone: 502.417.6664

The purpose of this project is to build a consortium of lung transplant centers wherein blood samples will be collected to evaluate the humoral and immune response of lung transplant recipients to vaccinations, such as COVID-19 and influenza. Th ... Read more >